Cantor Fitzgerald Reiterates Overweight on Biomarin Pharmaceutical, Maintains $110 Price Target
Biomarin Pharmaceutical Analyst Ratings
Analysts' Top Healthcare Picks: BioMarin Pharmaceutical (BMRN), Cigna (CI)
BioMarin Pharmaceutical: Hold Rating Amidst Growth Potential and Competitive Challenges
Buy Rating Affirmed for BioMarin Pharmaceutical Amid Strong Voxzogo Outlook and Strategic Growth Initiatives
BMO Capital Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $115
BofA Securities Initiates Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Announces Target Price $130
Jefferies Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Raises Target Price to $126
BioMarin Pharmaceutical Price Target Raised to $95.00/Share From $86.00 by Scotiabank
Piper Sandler Maintains Overweight on Biomarin Pharmaceutical, Raises Price Target to $122
A Quick Look at Today's Ratings for Biomarin Pharmaceutical(BMRN.US), With a Forecast Between $93 to $130
BioMarin Pharmaceutical Is Maintained at Buy by Truist Securities
Biomarin Pharmaceutical Analyst Ratings
BioMarin Pharmaceutical (BMRN) Gets a Buy From TD Cowen
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV) and BioMarin Pharmaceutical (BMRN)
Barclays Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)
BioMarin Pharmaceutical: A Buy Rating Based on Strong Growth and Operational Efficiency Strategy
Bernstein Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $110
Piper Sandler Maintains Overweight on Biomarin Pharmaceutical, Maintains $107 Price Target
Analysts Offer Insights on Healthcare Companies: Ginkgo Bioworks Holdings (DNA), BioMarin Pharmaceutical (BMRN) and Tactile Systems Technology (TCMD)